Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis

A. Céspedes-Cruz, R. Gutiérrez-Suárez, A. Pistorio, A. Ravelli, A. Loy, K. J. Murray, V. Gertoni, N. Wulffraat, S. Oliveira, J. Walsh, I. Calvo Penades, M. G. Alpigiani, P. Lahdenne, C. Saad-Magalhães, E. Cortis, L. Lepore, Y. Kimura, C. Wouters, A. Martini, N. Ruperto

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To examine the change in health-related quality of life (HRQOL) and its determinants in children with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). Methods: Patients were extracted from the PRINTO clinical trial which aimed to evaluate the efficacy and safety profile of MTX administered in standard, intermediate or higher doses (10, 15 and 30 mg/m2/week respectively). Children with polyarticular-course JIA, who were less than 18 years and had a complete HRQOL assessment were included. Results: A total of 521 children were included. At baseline, patients with JIA showed poorer HRQOL (p

Original languageEnglish
Pages (from-to)309-314
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume67
Issue number3
DOIs
Publication statusPublished - Mar 2008

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis'. Together they form a unique fingerprint.

Cite this